VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) announces with tremendous sadness the passing of our fellow director and colleague, Graham Wheelock. Graham served on K92’s Board of Directors continuously from February 2016, having been appointed to the Board of K92 when the Company first began trading in 2016. Graham’s extensive mining career as a geologist and mining professional spanned over 40 years working for international ...

Company Highlights Strategic Transition to Artificial Intelligence Data Centers and Reports Growth in Certain Business UnitsLAS VEGAS, May 05, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced preliminary financial results for the first quarter of 2025, which ended March 31, 2025, with revenue surpassing $25 million. The Company also issued guidance for the full fiscal year 2025, projecting revenue betwee ...

Delivers Approximately 18% Net Sales GrowthStrong Operating Performance on Input, Quality and Logistics CostsUpdates 2025 Outlook BEDMINSTER, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Compared to Prior Year Period Net sales of $263.2 million, an increase of 17.6%.Net loss of $12.7 million, compared to the prior year period net income of ...

PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted ea ...

In 2019, Elanco exclusively licensed lotilaner to Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) for exploration as a solution to several unmet human health needs. In 2023, XDEMVY became the first lotilaner- based product approved for human use and the only FDA-approved medicine for treatment of Demodex blepharitis (DB), a common eyelid disease in humans caused by Demodex mites. "Elanco's team of scientific experts is focused on identifying and developing molecules to generate high-impact innovation, not just ...

Company to use facility to further development of RetinalGenix’s therapies for neurodegenerative and retinal diseasesAPOLLO BEACH, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today a new laboratory lease agreement with life science incubator MBC BioLabs for a brand new facility located in San Carlos, California. The lease includes an option for Mission BioCapital, an affiliate of MBC Biolabs, to potentially invest in Retina ...

Core Insights - Atos has launched the SecureHorizons NIS2 Compliance Manager Application, powered by ServiceNow, to automate compliance processes for organizations facing the NIS2 Directive [1][4] - The NIS2 Directive aims to enhance cybersecurity across the EU, making compliance mandatory for all companies operating within or trading in the EU [2][3] Company Overview - Atos is a global leader in digital transformation with approximately 74,000 employees and annual revenue of around €10 billion [8] - The company specializes in cybersecurity, cloud services, and high-performance computing, providing tailored solutions across 68 countries [8] Product Features - The SecureHorizons application replaces manual processes with automated workflows, offering a unified dashboard for compliance monitoring [4][7] - It integrates people, processes, and technology to streamline compliance efforts and reduce enterprise risk [7] - The application is designed to help organizations proactively address compliance gaps and respond to audit requirements [5][6]

COSTA MESA, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) announced today that Stephen G. Oswald, the Company’s chairman, president and chief executive officer will participate in the upcoming 2025 Truist Securities Industrials & Services Conference on May 8, 2025, with one-on-one investor meetings scheduled throughout the day. Institutional investors are welcome to contact Truist to arrange one-on-one meetings with management. About Ducommun Incorp ...

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare techno ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven reviewPartnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseasesPlatform and Operations: Implemented meaningful s ...